Advanced Therapies Platform
- Presentation
- Projects
- Contact
La Advanced Therapies Platform has as its main objective to promote the development and implementation of new therapies at Parc Taulí, to accelerate the transfer of scientific discoveries into clinical practice, driving more efficient and personalized therapies. To make this possible, the platform promotes clinical trials, research and innovation to validate the effectiveness and safety of these therapies, following the strategic line established by Parc Taulí.
The Platform works under the coordination of:
The Pharmacogenomics and Advanced Therapies Unit, within the Center for Genomic Medicine, will be the unit responsible for overseeing the activity of clinical trials in advanced therapies.
Likewise, the Advanced Therapies working group supports the Advanced Therapies Platform, in collaboration between the Parc Taulí Research and Innovation Institute (I3PT) and the Center for Genomic Medicine. Together they have developed the Functional Plan to promote Phase I clinical trials and Advanced and Personalized Therapies.
Currently, Parc Taulí participates in four clinical trials and carry out research studies in advanced therapies, presented in the following table:
Advanced Therapies at Parc Taulí |
|||||||||
| Study | EudraCT Number | Promotor | IP | gene | cellular | tissue | combined | ||
| DELIVERY | Randomized, placebo-controlled, double-blind, multicenter phase IIb study to evaluate the efficacy and safety of HepaStem in patients with acute and chronic liver failure (ACLF) – DHELIVER. | Phase IIb | 2019-003051-11 | Promethera Therapeutics | Jordi Sánchez Delgado | Allogeneic off-the-shelf, liver-derived stem cell therapy | |||
| TANGELO (BP41674) | Open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7248824 in participants with Angelman Syndrome. | Phase I | 2019-003787-48 | Roche Pharma | Ana Roche Martinez | UBE3A-LNA (Locked nucleic acid) | |||
| GTX-102-001 | Phase 1/2, open-label, multiple-dose, dose-escalation clinical trial to evaluate the safety and tolerability of GTX-102 in pediatric patients with Angelman syndrome (AS). | Phase I/II | 2021-001793-36 | Ultragenyx Pharmaceutical Inc. | Ana Roche Martinez | Antisense Oligonucleotide (ASO) | |||
| FIDELIA (ZYA38771 ) | Implantation of skeletal muscle-derived cells for the treatment of faecal incontinence: a phase III, randomized, controlled, double-blind, two-treatment-arm clinical study. | Phase III | 2021-001376-42 | Innovacell AG | Laura Mora López | Skeletal Muscle-Derived Cell Implantation | |||
| Nano4Sepsis/NanoCares | Ramón Areces Foundation, I3PT, ESICM. Currently applied to La Caixa Health Research 2023 and preparing the project for the AES 2024 | Antonio Artigas/Marta Camprubí-Rimblas | Nanocapsules | ||||||
Advanced Therapies Platform
Parc Taulí Research and Innovation Institute
Plaça Torre de l'Aigua, s/n,
08208 Sabadell
- 93 723 10 10
- vmmartinez@tauli.cat